English

Annual General Meeting of BioGaia

Report this content

The Annual General Meeting of BioGaia AB (publ) on 6 May 2021 voted, among other things, to approve the following resolutions:

  • adoption of the annual report
  • discharge from liability for the Board members and the CEO
  • a dividend of SEK 3.41 per share and a grant of SEK 2.8 million to “The Foundation to Prevent Antibiotic Resistance” that was founded by BioGaia in 2017. The purpose of the foundation is to reduce antibiotic resistance through support to research, education and information activities that promote of the use of products and methods that prevent and therefore reduce the use of antibiotics and the risk of antibiotic resistance
  • on amendments to the articles of association in accordance with the board’s proposal to adjust the maximum permitted number of Board members to the nomination committee’s proposal
  • the number of Board members shall be nine without deputies
  • re-election of Ewa Björling, Maryam Ghahremani, Vanessa Rothschild, David Dangoor, Peter Elving, Anthon Jahreskog, Niklas Ringby and Peter Rothschild and new election of Christian Bubenheim as board members
  • re-election of Peter Rothschild as board chairman and David Dangoor as deputy board chairman
  • re-election of the registered accounting firm Deloitte AB
  • board member remuneration in an amount of SEK 650,000 to the board chairman, SEK 450,000 to the vice board chairman, SEK 250,000 to each of the other board members elected by the general meeting, SEK 100,000 to the chairman of the audit committee and SEK 50,000 each to the other members of the audit committee and SEK 40,000 to the chairman of the remuneration committee and SEK 20,000 to each to the other members of the remuneration committee 
  • an additional, monthly remuneration of not more than SEK 50,000 to the chairman of the board for duties in addition to the assignment as chairman of the board. Any such additional remuneration shall be paid according to separate agreement and the Board’s detailed decision
  • auditors’ fee shall be paid according to approved account
  • on a nominating committee in accordance with the nominating committee’s proposal
  • approval of the Board of Director’s remuneration report, and
  • implementation of an incentive program via a directed issue of new warrants to a subsidiary and approval of the transfer of warrants to participants in the incentive program.

CEO presentation at the Annual General Meeting is available on BioGaia's website.


Latest press releases from BioGaia
06.05.2021    Interim Management Statement January – March 2021
13.04.2021    Combination of L. reuteri strains reduces symptoms in children with sore throat
08.04.2021    BioGaia signs exclusive agreement in Egypt

For additional information please contact
Isabelle Ducellier, CEO: +46 8 555 293 00

BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia's probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com​​​​​​​

Subscribe

Documents & Links